Table 8.
Summary of under-investigation novel immunotherapies involving GI tract cancers
| Strategy | Category | Target | Regimen | Status | Sample size(estimated) | NCT number |
|---|---|---|---|---|---|---|
| Cell therapy | CAR-T cells | CLDN18.2 | AZD6422 | Recruiting | 96 | NCT05981235 |
| EpCAM | EPCAM CAR-T cells | Recruiting | 48 | NCT05028933 | ||
| GCC | IM96 CAR-T cells | Recruiting | 19 | NCT05287165 | ||
| GCC | LCAR-G08 cells | Recruiting | 42 | NCT06197178 | ||
| CEA | CEA CAR-T cells | Recruiting | 36 | NCT06010862 | ||
| LGR5 | LGR5-targeted CAR-T Cells | Recruiting | 45 | NCT05759728 | ||
| MSLN | αPD-1-MSLN-CAR T Cells | Recruiting | 30 | NCT05089266 | ||
| B7-H3 | anti-CD276 CAR T cells | Recruiting | 100 | NCT04432649 | ||
| CAR-T/TCR-T cells | NY-ESO-1, DR5, EGFR vIII, Mesothelin | CAR-T/TCR-T cells | unknown | 50 | NCT03941626 | |
| Muti-targets | Cyclophosphamide/Fludarabine + CAR-T/TCR-T cells | unknown | 73 | NCT03638206 | ||
| TCR-T cells | NY-ESO-1 | TBI-1301 + Cyclophosphamide/TBI-1301 + Cyclophosphamide + Fludarabine | unknown | 9 | NCT02366546 | |
| PRAME | IMA203/IMA203CD8 product | Recruiting | 186 | NCT03686124 | ||
| CAR-NK92 cells | NKG2D | NKG2D-CAR-NK92 cells | Recruiting | 20 | NCT05528341 | |
| CAR-macrophage cells | HER-2 | HER-2-targeted CAR-M cell | Not yet recurting | 9 | NCT06224738 | |
| Tumour vaccine | mRNA vaccine | Personalized Neoantigen | Neoantigen tumor vaccine with or without PD-1/L1 | Recruiting | 30 | NCT05192460 |
| Personalized Neoantigen | SW1115C3 | Recruiting | 30 | NCT05198752 | ||
| Personalized Neoantigen | RO7198457 | Recruiting | 229 | NCT04486378 | ||
| Personalized Neoantigen | Cyclophosphamide + personalized neoantigen vaccine + Pembrolizumab | Recruiting | 36 | NCT05269381 | ||
| Dendritic Cell Vaccine | Neoantigen | Neoantigen DC Vaccine and Nivolumab | Recruiting | 60 | NCT04912765 | |
| ICIs Beyond PD-1/L1 | ICIs Beyond PD-1/L1 | TIGIT | A: Tislelizumab plus Ociperlimab B: Tislelizumab plus Placebo | Completed | 125 (actual) | NCT04732494 |
| TIGIT | Pembrolizumab/Vibostolimab | Recruiting | 610 | NCT05007106 | ||
| TIGIT | BAT6005 | Recruiting | 36 | NCT05116709 | ||
| LAG3 | BMS-986213 + chemotherapy | Completed | 274 (actual) | NCT03662659 | ||
| LAG3 | IBI 110 ± sintilimab | Recruiting | 268 | NCT04085185 | ||
| CTLA-4 | Pembrolizumab/Quavonlimab | Recruiting | 320 | NCT04895722 | ||
| MICA/B | CLN619 + Pembrolizumab | Recruiting | 410 | NCT05117476 | ||
| Oncolytic viruses | Oncolytic viruses | Oncolytic virus | IDOV-SAFE | Recruiting | 60 | NCT06380309 |
| Oncolytic virus | HX008 | Recruiting | 300 | NCT03866525 | ||
| Oncolytic virus | R130 | Recruiting | 20 | NCT05961111 | ||
| Oncolytic virus | T3011 | Recruiting | 233 | NCT05602792 |